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Abstract 
Goniodysgenesis is a developmental abnormality of the anterior chamber of the eye. It is 
generally considered to be congenital in dogs (Canis lupus familiaris), and has been associated 
with glaucoma and blindness. Goniodysgenesis and early-onset glaucoma initially emerged in Border 
Collies in Australia in the late 1990s and has subsequently been found in this breed in Europe and the 
USA.  The objective of the present study was to determine the genetic basis of goniodysgenesis 
in Border Collies. Clinical diagnosis was based on results of examinations by veterinary 
ophthalmologists of affected and unaffected dogs from eleven different countries. Genotyping 
using the Illumina high density canine single nucleotide variant genotyping chip was used to 
identify a candidate genetic region.  There was a highly significant peak of association over 
chromosome 17, with a p-value of 2 x 10-13. Expression profiles and evolutionary conservation 
of candidate genes were assessed using public databases. Whole genome sequences of three 
dogs with glaucoma, three severely affected by goniodysgenesis and three unaffected dogs 
identified a missense variant in the olfactomedin like 3 (OLFML3) gene in all six affected 
animals. This was homozygous for the risk allele in all nine cases with glaucoma and 12 of 14 
other severely affected animals. Of 67 reportedly unaffected animals, only one was 
homozygous for this variant (offspring of parents both with goniodysgenesis who were also 
homozygous for the variant). Analysis of pedigree information was consistent with an 
autosomal recessive mode of inheritance for severe goniodysgenesis (potentially leading to 
glaucoma) in this breed. The identification of a candidate genetic region and putative causative 
variant will aid breeders to reduce the frequency of goniodysgenesis and the risk of glaucoma 
in the Border Collie population.     
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Introduction 
Companion animals including cats, dogs and horses, suffer from a range of diseases, with both 
genetic and environmental aetiologies. The breed barrier created by registration requirements 
and breeding practices seeking to maximise compliance of animals with breed specifications, 
results in increased levels of matings between relatives (Asher et al. 2009) and means that 
purebred companion animals are particularly likely to suffer from recessive genetic conditions 
with large effect sizes. Understanding the genetic factors underlying these diseases is important 
to improve welfare within breeds. The strong linkage disequilibrium in such inbred populations 
means that small numbers of pedigree animals can be used to identify genetic regions of 
interest, making them excellent genetic models if the same disease affects humans.   
In response to the identification of putative causal variants, breeding strategies can be put in 
place to reduce the prevalence of conditions that impact on animal welfare, especially when a 
genetic test can be developed. However, the success of these approaches depends on 
understanding the mode of inheritance and level of genetic contribution to the disease, and 
ideally on identifying a causative variant that can be used to develop a test for genetic status.  
Primary glaucoma is a condition in which increased ocular pressure damages the retinal 
ganglion, leading to blindness (reviewed in (Fricker et al. 2016)). In dogs (Canis lupus 
familiaris) it can be preceded by goniodysgenesis (also known as mesodermal dysgenesis), a 
developmental abnormality of the eye characterised by narrowing or closure of the iridocorneal 
angle through which the aqueous humour drains. This is associated with alterations in the 
structure of the pectinate ligament which traverses the drainage angle, called pectinate ligament 
dysplasia (PLD) (Plummer 2013) (more properly pectinate ligament abnormality (Oliver et al. 
2017b)). In the Leonberger dog breed, goniodysgenesis has been associated with an increased 
risk of developing primary closed angle glaucoma (Fricker et al. 2016) and in Flat-Coated 
Retrievers, development of glaucoma is positively and significantly related to the severity of 
goniodysgenesis (Wood et al. 1998). Goniodysgenesis is generally considered to be congenital 
in dogs, although its subsequent progression varies among breeds. Severity is thought to 
increase with age in Leonbergers (Fricker et al. 2016) and Flat-Coated Retrievers (Pearl et al. 
2015) and was shown to be strongly associated with age in Dandie Dinmont Terriers, Basset 
Hounds, Flat-Coated Retrievers, Hungarian Vizslas and Golden Retrievers (Oliver et al. 2016; 
Oliver et al. 2017a). However, goniodysgenesis remained stable in Samoyeds (Ekesten and 
Narfstrom 1991) and was not associated with age in a small study of Border Collies (Oliver et 
al. 2017a).  
 Anecdotal reports suggest that sudden onset glaucoma leading to blindness with bilateral loss 
of eyes was seen initially in young Border Collies in Australia in the late 1990s. A similar, 
sudden onset glaucoma in young animals subsequently emerged in the UK Border Collie 
population, often in dogs that were related to the affected Australian Border Collies.  As 
breeders recognised that there was a potential issue, they began to voluntarily track the results 
of gonioscopies and reports of glaucoma in an online database (Border Collie Goniodysgenesis 
and Glaucoma Database; https://bc-glaucomadatabase.synthasite.com/). A number of dogs in 
the USA and Europe have now also been diagnosed with severe goniodysgenesis and glaucoma 
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(Border Collie Goniodysgenesis and Glaucoma Database). Goniodysgenesis in Border Collies 
was added to the Schedule B list of “Conditions Under Investigation” in the British Veterinary 
Association (BVA) Eye Scheme (http://www.bva.co.uk/Canine-Health-Schemes/Eye-
scheme/) and examination of pedigrees indicated it was highly prevalent in some Border collie 
lineages (see Anadune Border collie database: http://www.anadune.com/). In a recent study 
(Oliver et al. 2017a), 11 of 102 Border Collies (10.8%) were reported to have moderate or 
severe PLD (associated with goniodysgenesis). Seven (6.9%) were mildly affected. The Border 
Collie goniodysgenesis and Glaucoma Database lists 110 dogs which have been diagnosed as 
affected with goniodysgenesis, but only 12 who have developed glaucoma.  It is not known 
why a proportion of dogs diagnosed with severe goniodysgenesis go on to develop glaucoma 
but breeders report that some have lived for as long as 15 years and remain free of glaucoma.  
There is an apparent association with a small number of popular sires, and a genetic aetiology 
is strongly suspected in Border Collies, but the heritability and mode of inheritance of the 
condition is currently unknown. 
The aim of the current study was to perform a genome-wide analysis to find genetic regions 
that are associated with severe goniodysgenesis and glaucoma in the Border Collie and identify 
candidate variants that might be responsible for this condition. 
 
Materials and Methods 
Full details of the Materials and Methods, including details of publicly available data, are given 
in File S1. 
Ethical approval 
All studies were approved by the Veterinary Ethical Review Committee of the University of 
Edinburgh (approval number VERC 2012-8) and the Animal Ethics Committee of the 
University of Queensland (approval number ANFRA/MRI-UQ/565/17).  
Ascertainment of clinical status and pedigree 
Goniodysgenesis status for individuals in the study was obtained from a database of gonioscopy 
test results in Border Collies (Border Collie Goniodysgenesis and Glaucoma Database), or from 
official test certificates submitted by the owners.  Goniodysgenesis was diagnosed by 
veterinary ophthalmologists (such as members of the BVA Eye Panel in the UK or the 
equivalent certifying body in other countries) who examined the eyes with gonioscopy and 
assessed the status of the drainage angle and the pectinate ligament fibres that span it. 
Depending on the year and country of testing, results may have been given as “clinically 
unaffected/affected”, or there may have been more information about the extent of 
goniodysgenesis. Some reports specified both whether the angle was structurally narrow and 
the extent of PLD. Other results allocated a grade to the level of goniodysgenesis. An early 
grading scheme in the UK had Grade 1 being very mild and Grade 5 being severely affected. 
Currently a new grading scheme is being evaluated in the UK, with Grade 1 being mild and 
Grade 3 being severely affected (British Veterinary Association Eye Scheme). Since we had 
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results in multiple formats, each report was manually assessed to assign clinical status to each 
subject. Only individuals whose eyes had been examined using gonioscopy were included. 
Three cases with comorbidity (cataract, autoimmune disease) and one case where genotype 
results were inconsistent with official parentage were excluded from all analyses. 
Breeding records and pedigree data were obtained from Anadune Border Collie database 
(http://www.anadune.com/), which contains over 226,700 registered Border Collie dogs 
worldwide, from the Border Collie Pedigree Database (http://db.bordercollie.ru), with 20,217 
dogs, and from the breeders’ websites.  
A genome wide association study (GWAS) was undertaken using the more extreme 
phenotypes. As such, we defined cases as dogs that had goniodysgenesis of grades four or five 
under the early grading scheme, dogs whose goniodysgenesis was described as “severe”, those 
where the veterinary ophthalmologist report indicated PLD over more than 70% of the 
iridocorneal angle and those that developed glaucoma following a diagnosis of 
goniodysgenesis. Controls were dogs that were assessed as clear or clinically unaffected based 
on at least one gonioscopy examination. Previous work did not show age-related progression 
of goniodysgenesis in Border Collies (Oliver et al. 2017a) so the controls were those with a 
clear gonioscopy, regardless of age. 
Genetic analysis 
DNA samples were from buccal cells collected by owners and occasionally from blood. Full 
details of collection and extraction procedures are given in File S1. Genotyping used the 
Illumina 173K CanineHD Whole-Genome Genotyping Bead Chip (Illumina, San Diego, CA, 
USA) and was performed by Edinburgh Genomics, University of Edinburgh, UK. Results were 
filtered in PLINK v1.07 (Purcell et al. 2007) to remove individuals that had more than 10% of 
missing genotypes and markers that had rates of genotyping < 0.95, had minor allele frequency 
< 0.05 in this population or deviated from the Hardy-Weinberg equilibrium in the controls with 
p value of less than 0.0001. Only the autosomes were considered. 
The GWAS was performed in GEMMA v0.94.1 (Zhou and Stephens 2012) using a linear 
mixed model approach, controlling for relatedness using a SNV-based relatedness matrix as a 
random effect. The significance threshold was 4.8 x 10-7 calculated using an uncorrected  P 
value of 0.05 adjusted for testing on 104,141 segregating SNVs (Bonferroni correction).  
Whole genome sequencing (WGS) at 30X coverage of DNA from three dogs with glaucoma, 
three with severe goniodysgenesis and three unaffected animals was performed using the 
Illumina HiSeq X platform. Library insert sizes were 450 bp and paired reads of 150 bp were 
sequenced. Library preparation and sequencing was performed by Edinburgh Genomics. Reads 
were processed by standard procedures, detailed in File S1 and mapped to the CanFam3.1 
reference genome. The significance of variants was assessed using PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2), Mutation Taster (http://www.mutationtaster.org), 
Provean (http://provean.jcvi.org) and SIFT (scores obtained from Provean analysis). Structural 
variants were ascertained with DELLY 0.7.7 (Rausch et al. 2012) and GRIDSS 2.0.1 (Cameron 
et al. 2017) . 
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Transcriptomic analysis of candidate region genes 
A time course of mouse eye development from embryonic day 12 to adult was examined using 
the FANTOM5 database (Forrest et al. 2014; Arner et al. 2015; Summers and Hume 2017) 
(http://fantom.gsc.riken.jp/zenbu). FANTOM5 data were also used to obtain expression levels 
for human eye-related samples (Table S1). Transcriptomic data for the developing chicken eye 
were generated for another project by RNA sequencing methodology (Rainger J et al, 
submitted). Details are given in File S1. Microarray-based expression data for a range of tissues 
in human and mouse were from BioGPS (http://biogps.org) as were RNA sequencing data for 
chicken tissues. Microarray expression data for immune cell types was derived from the 
Immunological Genome Project (https://www.immgen.org/). 
Analysis of canine OLFML3 and CDK2AP1 genes  
The region of the canine OLFML3 gene containing the candidate causative variant was 
amplified by the polymerase chain reaction and the amplicon sequenced by chain termination 
sequencing (Australian Genome Research Facility (AGRF), Brisbane, Australia or Edinburgh 
Genomics, University of Edinburgh, UK). The change associated with the variant in the 
CDK2AP1 gene created a cutting site for the restriction enzyme Hinf1. DNA was amplified by 
the polymerase chain reaction and treated with Hinf1 to identify the uncut (wild type) and cut 
(risk) alleles. The genotypes of a number of samples of all genotypes were validated using 
chain termination sequencing (AGRF). Full details of primers and protocols are given in File 
S1.  Sequences for analysis of nucleotide and amino acid conservation across species were 
downloaded from Ensembl (http://www.ensembl.org) and alignment was performed using 
Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). 
Data availability 
The SNV data used in the GWAS are available via the University of Edinburgh data repository 
at http://dx.doi.org/10.7488/ds/2426. BAM files for the WGS are available via the European 
Nucleotide Archive, accession numbers ERS2643230 and ERS2643240-7. The variant calls 
for OLFML3 and CDK2AP1 are available in Table S3.  
 
Results  
Genome wide association analysis 
To identify genetic regions associated with goniodysgenesis in this breed, we performed a 
GWAS on 17 cases (8 female, 9 male) with goniodysgenesis described as “severe” (N=4), 
Grade 4 or 5 by the earlier grading scheme (N=1 and 5 respectively), or goniodysgenesis 
followed by glaucoma (N=7). Controls were 42 dogs (26 female, 16 male) who had been passed 
as “clinically unaffected” at veterinary ophthalmology testing. A strong association of 
goniodysgenesis with a region of chromosome 17 was found (Figure 1A). The lowest p-value 
was for SNV rs22561716 at 17:51,919,221 (p=2 x 10-13). Genotypes for this variant are shown 
in Table 1. SNVs with significant p-values (p ≤ 4.8 x 10-7) were in a region of 3.8 Mbp between  
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Table 1. Genotype frequencies for the most significant SNV, rs22561716, in severely affected and 
unaffected dogs from the GWAS analysis. 
Genotype for rs22561716 
 
Clinical Status 
TT TG GG TOTAL 
Glaucoma 7 0 0 7 
Severe goniodysgenesis 9 1 0 10 
Unaffected 1 21 20 42 
  
Figure 1. Genome wide association with severe goniodysgenesis and glaucoma 
A. Manhattan plot for the canine genome; chromosome 17 is shown in more detail and genes 
in the region are shown below. Thick bars show known large structural variants and the 
bracket indicates the location of the break in synteny between dog and other mammals. Red 
line shows the Bonferroni significance level (4.8 x 10-7). Genes in bold are those where a 
coding sequence variant was detected. 
B. QQ-plot for the GWAS analysis. The lambda value is 1.07. 
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17: 49,879,074 and 17:53,632,785 (Figure 2). This region contains a break in synteny where 
the mapped genes are continuous in the dog and on different chromosomes in other mammals; 
the break occurs between PAIB2B/NAGK and PHTF1 (indicated by a bracket in Figures 1 and 
2). The region also contains a number of large structural variants including deletions and 
inversions (the largest are indicated by thick bars in Figures 1 and 2) (Decker et al. 2015).  
 
There was a block of shared homozygosity in affected animals from 17:50,895,797 (distal to 
rs9159262) to 17:51,666,793 (proximal to rs22582070) (indicated in Figure 2). This did not 
include the SNV with the lowest p-value (rs22561716 at 17:51,919,221), which lay just beyond 
Figure 2. Homozygosity within the region of significant SNVs, CanFam3.1 17:49,879,074-
53,632,785. Each row is a DNA sample and each column shows a variant. Only variants that 
were segregating in this population are shown. Red and yellow indicate homozygosity for 
the two alleles and green shows heterozygosity. The upper block shows animals with severe 
goniodysgenesis (above black line) and glaucoma (below black line); the lower block shows 
those passed as clinically unaffected at gonioscopy testing. The most significant SNV 
rs22561716 is yellow in the cases (homozygous for the risk-associated allele); one clinically 
unaffected animal was homozygous for this allele and one severely affected animal was 
heterozygous. SNVs rs9151262 and rs22582070 flank the block of homozygosity (heavy 
black arrow). rs22582070 and rs22582570 flank a second block where all cases except one 
were homozygous (light black arrow). SNV rs22556171 indicates the point at which the 
genotypes of full siblings BC6108 (affected) and BC6113 (unaffected) become the same. 
Genes underlying the SNVs are indicated by black bars; the relative proportions are different 
from Figure 1 reflecting the differing density of markers across the region. There were no 
segregating markers for RSBN1, BCL2L15, DCLRE1B, BCAS2, CDK2AP1, NRAS, 
ENSCAFG00000009671,  NGF or NHLH2. SNVs rs22597349 and rs22597351 flank the 
OLFML3 gene.  SNVs rs22562255 and rs22582380 flank the CDK2AP1 gene. SNVs 
rs22562255 and rs22582380 flank ENSCAFG00000009671.  Grey bars show known large 
structural variants and the bracket indicates the location of the break in synteny between dog 
and other mammals. 
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an apparent recombination breakpoint in one animal affected with Grade 5 goniodysgenesis. 
The region was further delineated because the full siblings BC6108 (affected) and BC6113 
(unaffected) were homozygous up to rs22556171. Therefore the region where all cases and no 
controls were homozygous for the risk allele extended from 17:51,510,172 (distal to 
rs22556171) to 17:51,666,973 (proximal to rs22582070) as shown in Figure 2. Within the 
genomic region identified by the association analysis there were a number of coding genes 
(Figure 1A), although none was known to be involved in abnormalities of eye development or 
development of glaucoma in animals or humans. Several had strong expression in the 
developing mouse eyeball (Figure S1). In particular there were three genes within the minimal 
overlap region (PHTF1, RSBN1, PTPN22). Ptpn22 had negligible expression in the developing 
mouse eye. Expression of Phtf1 was moderate in the embryonic eye and declined after birth. 
Expression of Rsbn1 was also moderate in the mouse eye, peaking in the early neonatal period 
(Figure S1). These genes were therefore considered to be candidates for the pathological 
variant in this condition.  
Variant detection by whole genome sequencing 
We then obtained the whole genome sequence of this region for three dogs with glaucoma, 
three severely affected with goniodysgenesis but without glaucoma and three unaffected 
individuals, who were members of four nuclear families (Figure S2). All were distantly related 
through multiple lineages in the extended pedigree. Relatives were chosen to highlight variants 
that were different between affected and unaffected family members (Lander and Botstein 
1987).  
There were no structural variants where all cases were the same and different from all controls. 
Several deletions were noted, but in general all animals carried these deletions (Table S2). This 
is consistent with the small number of segregating variants in this region, indicating a high 
level of homo- or hemizygosity. 
Our initial scan of the block of shared homozygosity (heavy arrow, Figure 2) revealed ten 
variants for which all cases were homozygous for the non-reference allele and controls were 
heterozygous or homozygous for another allele (green fill in Table S2). There were six 
annotated protein coding genes in this region but there were no coding sequence or frameshift 
variants. Six of the variants were intronic (two in DYSF, one in PIAP2B and three in RSBN1) 
and four were intragenic. Three of the intronic and one of the intragenic variants were located 
in the critical overlap region between 17:51,510,172 and 17:51,666,793 (dark green fill in 
Table S2). The intronic variants in RSBN1 all affect a tetranucleotide repeat (TAAA14) in the 
middle of the intron. The intronic variants in DYSF  affect a tetranucleotide repeat (TAAA11) 
and a string of 11 T residues. There was no evidence that any of these variants might be 
pathological. 
Since there were no potentially detrimental variants in the region of shared homozygosity, we 
considered DNA changes beyond the apparent recombination breakpoint (where one Grade 5 
affected animal became heterozygous) up to 17:52.484,845 (rs22582570) where three 
additional cases became heterozygous (Figure 2 and blue fill in Table S2). This region 
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included the most significant SNV. The other sixteen severely affected and glaucoma cases 
were homozygous in this region (Figure 2). Between the putative breakpoint at 17:51,666,793 
and 17:52,484,845 there were 15 annotated coding genes. The region contained 114 variants 
where the six sequenced cases were all homozygous and the controls were heterozygous or 
homozygous for another allele. Two variants were missense and one was synonymous. There 
were 19 intron variants and the remainder were intergenic or in the up- or downstream gene 
regions (Table S2). 
A missense variant was found in the olfactomedin like 3 (OLFML3) gene, at position 
17:51,786,924 (CanFam3.1, Ensembl), between rs22597349 and rs22597351 and close to the 
most significant SNV (Figure 2). The variant is ENSCAFT00000014855.3:c.590G>A with the 
predicted change of arginine (codon CGG) to glutamine (codon CAG) at position 197 
(ENSCAFP00000013747.3:p.(Arg197Gln)). This arginine is in the olfactomedin (OLF) 
domain (Rodriguez-Sanchez et al. 2013; Zeng et al. 2005) (Figure 3A) and was found to be 
highly conserved throughout mammals, birds and reptiles (Figure 3B). In humans, the 
equivalent variant (ENST00000320334.4:c.587G>A) corresponds with rs377336789 
(https://www.ncbi.nlm.nih.gov/snp/) and was seen in four out of 120,920 alleles with a minor 
allele frequency of 3.3 X 10-5; no homozygotes were seen (Exome Aggregation Consortium, 
http://exac.broadinstitute.org; (Lek et al. 2016)). The variant effect prediction program 
PolyPhen-2  gave a score of 0.888, considered “possibly damaging”. Another effect prediction 
program, Mutation Taster, considered the variant to be “disease causing” with potential 
changes to the protein features and a possible splice site change. In contrast, Provean found 
that the variant was likely neutral (score: 0.03). The SIFT score for the human variant was 
0.429, categorised as “tolerated”.  
The A allele was not seen in 213 genotypes from 12 dog breeds (not including Border Collies) 
and four wolf populations from the Multiple Dog Genome Project 
(https://www.ebi.ac.uk/eva/?eva-study=PRJEB24066). Four of 34 Border Collies from the 
Dog Biomedical Variant Database Consortium (DBVDC) were heterozygous (giving an allele 
frequency of 0.055 in this breed) but the A allele was not seen in 504 genotypes of other breeds. 
Notably, it was not present in 51 Leonbergers, three Basset Hounds, eight Golden Retrievers, 
one Flat Coated Retriever, three Welsh Springer Spaniels or one Dandie Dinmont Terrier, all 
breeds reported to have a high prevalence of goniodysgenesis (Table S3). In addition, 350 dogs 
recorded as Border Collies but of unknown clinical status were genotyped by Animal Genetics 
(Talahassie, Florida, USA) via allele-specific PCR run on an ABI 3730 machine. There were 
2 homozygotes and 29 heterozygotes among these 350 Border Collies, giving an allele 
frequency of 0.05, consistent with the smaller sample from the Consortium. 
Taken together the evidence suggested that the OLFML3 variant was likely to have a mild to 
moderate effect on the protein. The greatly increased frequency in the cases is strong support 
while the conflicting computation and predictive data provides weaker support (Richards et al. 
2015). Segregation with severe goniodysgenesis/glaucoma was observed within families (as 
seen in the nuclear families from the WGS and also in additional families where the OLFML3 
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genotype was established), providing strong support for likely pathogenesis (Richards et al. 
2015). We therefore examined this gene further. 
OLFML3 genotypes of severely affected and unaffected Border Collies 
The results for the OLFML3 variant ENSCAFT00000014855.3:c.590G>A in glaucoma, severe 
goniodysgenesis and unaffected dogs are shown in Table 2. The individual who was 
heterozygous for the region based on SNV results was also AG at OLFML3. This animal had 
been diagnosed with Grade 5 goniodysgenesis but did not develop glaucoma over a 15-year 
lifespan. In addition, one unaffected dog was AA genotype. This animal was the offspring of a 
severely affected (grade 5) father and a mother diagnosed as affected (with no grade). Both 
parents were also AA. Under some testing schemes animals could pass with a degree of 
goniodysgenesis (Fricker et al. 2016; Oliver et al. 2017b) which may be the case with this dog. 
In general, the genotype for OLFML3 segregated with that for rs22561716, indicating strong 
linkage disequilibrium between them. However, an unaffected mother and son were 
homozygous for G at OLFML3 but heterozygous at rs22561716 (shown by the different 
numbers of heterozygotes and wild type homozygotes in Table 1 and Table 2). In addition, 
two unaffected individuals were homozygous for several SNVs either side of OLFML3 but 
heterozygous for the OLFML3 variant and rs22561716. 
To validate these results, we genotyped 31 additional Border Collies that had had gonioscopy 
investigations: two with glaucoma (both female), four with severe goniodysgenesis (all female) 
and 25 unaffected (10 male, 15 female). The genotypes of this replication set of dogs are shown 
in Table 2 and are consistent with the results suggesting that severe goniodysgenesis/glaucoma 
was associated with homozygosity for the A allele of OLFML3. 
Table 2. Genotype frequencies for OLFML3 mutation c.590G>A in severely affected and unaffected 
dogs. 
                   Genotype for OLFML3 
Clinical status 
AA AG GG TOTAL 
GWAS dogs1     
Glaucoma 7 0 0 7 
Severe goniodysgenesis 9 1 0 10 
Unaffected 1 19 22 42 
Replication dogs     
Glaucoma 2 0 0 2 
Severe goniodysgenesis 3 1 0 4 
Unaffected 0 17 8 25 
TOTALS     
Glaucoma 9 0 0 9 
Severe goniodysgenesis 12 2 0 14 
Unaffected 1 36 30 67 
 
1 Dogs that were included in the genome wide analysis (GWAS dogs) are shown separately from dogs 
in the replication set that were only tested for OLFML3. 
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Figure 3. Conservation of OLFML3 predicted amino acid sequence 
A. Amino acid sequence of the canine OLFML3 protein. Functional domains are 
highlighted: blue – signal peptide; pink – coiled coil domain; yellow – olfactomedin like 
domain (Zeng et al. 2005; Rodriguez-Sanchez et al. 2013). Within the yellow region, bold 
lettering shows the core OLF region. Green shows the arginine at position 197. 
B. Conservation of arginine 197 (green) in OLFML3 of vertebrates. Arginine is found at the 
equivalent position in all mammal, bird and reptile species for which there is an annotated 
OLFML3 gene, and in coelacanth but not in other fish. The region around this arginine is 
also highly conserved.  
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OLFML3 genotypes in mildly affected and uncategorised affected Border Collies 
Our initial analysis compared dogs affected with severe goniodysgenesis or glaucoma with 
dogs passed as clinically unaffected at gonioscopy examination. Because of changes in the 
reporting scheme in the UK and differences among countries, there were a number of equivocal 
diagnoses. These were dogs for which either the degree of goniodysgenesis was reported as 
mild (Grade 1 under the former scheme or stated as mild or marginal on the report; N = 9; five 
female, four male), moderate (Grade 2 – 3 under the old scheme, or stated as moderate or 
between 25 and 70% blocked on the report; N = 9; eight female, one male), or the dogs were 
diagnosed as affected with goniodysgenesis with no description given (N = 15; nine female, 
six male). To examine whether OLFML3 was involved in these cases we genotyped these 33 
dogs. The results are shown in Table 3. All three genotypes were found among these cases. 
Table 3. Genotype frequencies for OLFML3 mutation c.590G>A in mild, moderate and 
uncharacterised affected dogs. 
                   Genotype for OLFML3 
Clinical status 
AA AG GG TOTAL 
     
Mild 3 3 3 9 
Moderate 4 2 3 9 
Affected, no grade 7 3 5 15 
TOTALS 14 8 11 33 
 
Expression of OLFML3 in the eye 
In expression data generated by the FANTOM5 project, the Olfml3 gene was strongly 
expressed in mouse eyeball at embryonic and neonatal stages and declined in the adult sample 
(Figure 4A). FANTOM5 data also showed that the gene was expressed in human lens, corneal 
epithelium and retina (Figure 4B), although the highest expression was in amniotic and 
placental epithelial cells and in mesenchymal stem cells (not shown). OLFML3 was also 
expressed in the developing chick eye, with highest expression at embryonic day 6 (Figure 
4C).  In mouse microarray data (mouse probeset 1448475_at; available at BioGPS, 
http://biogps.org) expression of Olfml3 was highest in osteoblasts undergoing calcification, but 
it was also found in eyecup, iris, ciliary bodies and lens (Figure S3A). There was negligible 
expression in immune system cells, except for macrophages, osteoclasts and particularly 
microglia, which had expression comparable to lens and eyecup. Strong expression in 
microglia was also seen in the Immunological Genome data set (Figure S3B). Human 
microarray data also available through BioGPS showed strongest expression of OLFML3 in 
adipocytes, uterus and retina, the only eye tissue represented (human probeset 218162_at; 
http://biogps.org) (Figure S3C). RNA sequencing data compiled on BioGPS revealed 
expression in many samples from the chicken, notably the whole embryo and connective 
tissues and the cornea of the adult (Figure 3D). Other OLF family members were also 
expressed in the developing mouse eyeball with a similar pattern to Olfml3, peaking in the early 
neonatal period and declining in the adult eye (Figure S4). In contrast, the myocilin gene 
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(encoding a related protein which is mutated in human open angle glaucoma) had negligible 
expression in embryo and early neonate but increased expression at neonatal day 16 and in 
adult eyeball (Figure S4). 
 
Other genetic variants in the region of interest 
Two other potentially damaging variants were found in the region of the most significant SNVs. 
One was a missense variant in the cell cycle gene CDK2AP1 
(ENSCAFT00000015099.1:c.236C>T; CanFam3.1 17:52,363,576). This would result in the 
substitution of leucine for proline at amino acid 79 (ENSCAFP00000041716.1:p.Pro79Leu). 
The gene has been mapped to three canine chromosomes on the UCSC browser 
(https://genome.ucsc.edu); a location on canine chromosome 26 is syntenic with the mapped 
Figure 4. Expression of OLFML3 genes in eye regions 
A. Expression of Olfml3 in developing mouse eyeball. Results are based on CAGE and were 
downloaded from the FANTOM5 database (http://fantom.gsc.riken.jp/5/tet). Y axix shows 
RLE normalised values. Light grey – embryonic samples; dark grey – neonatal samples; 
black – adult sample. 
B. Expression of OLFML3 in human eye tissues and cells. Results are based on CAGE and 
were downloaded from the FANTOM5 database. Y axis shows RLE normalised values. 
Light grey – optic nerve and retina; mid grey – cornea; dark grey – lens. 
C. Expression of OLFML3 in the developing chick eye. Results are based on RNA 
sequencing (from http://biogps.org).  Y axis shows transcripts per million (TPM) values. 
Light grey – embryonic day 5; mid grey – embryonic day 6; dark grey – embryonic day 7. 
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position of the gene in human and mouse, so there is some uncertainty about whether the region 
on chromosome 17 represents a functional gene, a pseudogene or an incorrect genome 
assembly. Using the equivalent human DNA change (matching the canine gene on 
chromosome 26), PolyPhen-2  gave a score of 0.995, considered “probably damaging”. 
Mutation Taster considered the variant to be “disease causing” with potential changes to the 
protein features. Provean  also found that the variant was likely deleterious (score: -8.44). In 
contrast the SIFT score for the human variant was 0.121, categorised as “tolerated”. This 
variant has been annotated as rs850595562 with an allele frequency of 0.05 in 218 canines (12 
dog breeds and four wolf populations), including three homozygotes (Multiple Dog Genome 
Project – Run 1; https://www.ebi.ac.uk/eva/?eva-study=PRJEB24066). There were no Border 
Collies in this dataset and none of the breeds included has been reported to have a 
predisposition to goniodysgenesis. The variant was found in 46 of 550 dogs in the DBVDC set, 
including eight homozygotes (Table S3). The allele frequency was quite high in Border Collies 
(12 heterozygotes and one homozygotes in 34 dogs) but also high in other breeds such the 
Dogue de Bordeau (three homozygotes and two heterozygotes in six dogs) and the Cane Corso 
(two homozygotes and two heterozygotes in five dogs). In contrast most other breeds known 
to be susceptible to goniodysgenesis and glaucoma were uniformly homozygous for the wild 
type allele, except for one Golden Retriever which was heterozygous. Targeted disruption of 
the gene in mouse (equivalent to the chromosome 26 gene in dog) resulted in a high incidence 
of embryonic lethality (Kim et al. 2009). The presence of multiple versions of this gene in the 
canine genome may explain the apparent lack of phenotype associated with this variant in the 
dog and suggests the possibility that the chromosome 17 gene is non-functional. The majority 
of the dogs with severe gonidysgenesis or glaucoma were homozygous for the risk allele 
(Table S4). However, two unaffected dogs were also homozygous for the risk allele and two 
goniodysgenesis affected dogs were heterozygous. The variant was in strong linkage 
disequilibrium with the most significant SNV, but there were a number of examples with 
apparent recombinant haplotypes. This variant seemed unlikely to be causal for severe 
goniodysgenesis in Border Collies.  
A potentially damaging variant was found beyond the region of greatest homozygosity (distal 
to rs22582570, flanked by rs2222562255 and rs22582380). This was a frameshift variant 
involving deletion of the second nucleotide of exon 7 of ENSCAFG00000009671 (CanFam3.1 
17:52,526,443-52,536,071), encoding a putative protein orthologous to mouse nuclear receptor 
NR1H5. The Nr1h5 gene has negligible expression in the developing mouse eye and is 
represented by a pseudogene in the human genome.  All genotypes for the variant were found 
in the Multiple Dog Genome Project. All carried the reference sequence while controls were 
heterozygous for this and the deletion and it was unlikely that this would be the cause of their 
severe goniodysgenesis and glaucoma.  
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Discussion 
In a number of dog breeds development of glaucoma has been associated with the presence of 
goniodysgenesis. In the Flat-Coated Retriever, the likelihood of glaucoma was positively and 
significantly related to the severity of goniodysgenesis (Wood et al. 1998) and in the 
Leonberger five unilateral glaucoma-affected individuals all had a high grade of 
goniodysgenesis in the contralateral eye (Fricker et al. 2016). An abnormal drainage angle is 
considered typical of some breeds, with reports of up to 81% of individuals showing evidence 
of goniodysgenesis (Ekesten and Narfstrom 1991; Kato et al. 2006). However, goniodysgenesis 
does not necessarily proceed to glaucoma. For example, one study found that 25% of Samoyeds 
had some level of PLD, but only 3% had developed glaucoma (Ekesten and Narfstrom 1991). 
The highest prevalence of glaucoma (all forms) reported in any single breed is only 5.52% (in the 
American Cocker Spaniel) (Gelatt and MacKay 2004). 
An increasing incidence of glaucoma in young animals of the Border Collie breed has been 
anecdotally reported by breeders over the last 15 years. Inspection of available Border Collie 
pedigrees revealed that there were three common ancestors in both the sire and dam lineages 
for all cases of glaucoma on the Border Collie Goniodysgenesis and Glaucoma Database  
(N=12, including two pairs of full siblings both affected with glaucoma), as well as additional 
cases not on the database (N=4). These common ancestors dated back to the late 1970s and 
early 1980s and were found in multiple ancestral lineages for the glaucoma cases. All the 
glaucoma cases had been diagnosed with goniodysgenesis and subsequently had one or both 
eyes removed. Consistent with results in other breeds, we found some Border Collies who lived 
entire lifetimes with apparently severe goniodysgenesis without developing glaucoma. This 
included two popular sires who reached the age of 15 years without a diagnosis of glaucoma, 
although they had produced puppies who did develop glaucoma; three dogs with severe 
goniodysgenesis had produced a total of six offspring with glaucoma. It also included a full 
sibling of two dogs with glaucoma. Although severe goniodysgenesis is important in the 
progression to glaucoma, it is not the sole cause. The aetiology may involve a genetic 
predisposition to goniodysgenesis combined with genetic, environmental or random factors 
influencing development of glaucoma.  
The diagnosis of goniodysgenesis was made by veterinary ophthalmologists (such as members 
of the BVA Eye Panel in the UK or the equivalent certifying body in other countries) who 
performed gonioscopies to assess the status of the drainage angle and the pectinate ligament 
fibres that cross it. Since the diagnoses were made by a number of different clinicians over a 
period of years, there may be considerable noise in the phenotype. An initial eye scheme 
developed by the BVA in association with the Kennel Club of the United Kingdom involved 
assessing whether the dog had no eye abnormality (a pass), or some abnormality graded from 
one to five according to the extent of PLD and the width of the iridocorneal angle, in increasing 
levels of severity. Since there was a high degree of inter-observer variability in assigning a 
grade, the scheme was subsequently amended such that the dog would be reported as either 
clinically unaffected or affected. Dogs that were considered unaffected could have a drainage 
angle that was abnormal to some extent (“mild” goniodysgenesis; see information available at 
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https://www.bva.co.uk/Canine-Health-Schemes/Eye-scheme/). The binary scheme was 
expected to have a higher level of inter-observer agreement. This was confirmed in a recent 
study of Leonberger dogs (Fricker et al. 2016) where there was a high correlation in proportion 
affected with goniodysgenesis between a prospective study where examinations were 
performed by a single specialist (2012-2014; 18% affected) and a retrospective study of BVA 
eye scheme certificates (2009-2014; 22% affected). In a study of PLD in Welsh Springer 
Spaniels, there was a good correlation between two examiners in determining unaffected eyes, 
although there was considerable variability between examiners in assigning the degree of PLD 
(Oliver et al. 2017b). This variability in categorising the extent of goniodysgenesis means that 
the classification of phenotype “clinically unaffected” individuals can have mild PLD or angle 
narrowing (Fricker et al. 2016; Oliver et al. 2017b). For this reason, we focussed our genome-
wide analysis on severely affected dogs including several that had gone on to develop 
glaucoma.  
Using dogs with severe goniodysgenesis or goniodysgenesis followed by glaucoma as cases 
and clinically unaffected dogs as controls, we found a strong peak of association on 
chromosome 17, with a stretch of shared homozygosity of about 1 Mbp. However, whole 
genome sequencing of three control, three glaucoma and three severe goniodysgenesis dogs 
showed that there were few variants in this region where the cases were all of the same 
genotype and different from all controls. Variants in this region were all either intronic or 
intragenic and there were no coding sequence variants. Intronic variants all affected short 
microsatellite repeat regions. Dogs have a high level of unstable microsatellites in coding or 
non-coding regions, sometimes associated with disease (Fondon and Garner 2004; Forman et 
al. 2015). However the repeat length changes in DYSF and RSBN1 were small (± 1-3 repeat 
units) in the middle of introns and were found in a number of breeds in the Multiple Dog 
Genome Project. They seemed unlikely to be pathogenic. The number of segregating SNVs in 
this region was low and all animals carried a number of deletions across the region.  
Slightly distal to this region but where 16 of 17 cases were still homozygous in the GWAS, 
and closer to the most significant SNV, we detected two missense variants. One, in CDK2AP1, 
was felt unlikely to be causative. Homozygotes for the risk allele were found in a range of 
breeds in which goniodygsenesis has not been reported and the allele frequency was relatively 
high across all breeds. We also found two unaffected dogs who were homozygous for this 
allele. The presence of three orthologues of CDK2AP1 in the canine genome suggested that 
there was redundancy, potentially with the gene in the region of interest being non-functional.  
A frameshift mutation in ENSCAFG00000009671 was also segregating in Border Collies, but 
all the cases were homozygous for the reference allele, making it unlikely that this was the 
cause of the condition. 
We also detected a missense variant,  ENSCAFP00000013747.3:p.Arg197Gln, in the OLFML3 
gene. We propose that this variant is a candidate for severe goniodysgenesis potentially leading 
to glaucoma in the Border Collie, based on the presence of the variant only in this breed, the 
probability that there is some deleterious effect from the amino acid change, strong 
conservation of the sequence in vertebrates including non-mammalian species and the 
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segregation of the variant with clinical status in canine families. In addition, spatial and 
temporal expression patterns of the gene are consistent with a role in eye development. 
Although this gene has not been implicated in goniodysgenesis or glaucoma in humans, it is 
strongly expressed in tissues of the anterior segment of the human and baboon eye including 
lens, iris, sclera and trabecular meshwork (Rodriguez-Sanchez et al. 2013; Tomarev and 
Nakaya 2009) and in the developing mouse eye (Ikeya et al. 2005) . The Olfml3 gene was 
expressed throughout mouse eye development (Figure 4A) and during chick eye development 
(Figure 4C). In mouse, inactivation of the Olfml3 gene by insertion of a Lac cassette resulted 
in viable and fertile homozygotes (Ikeya et al. 2005), consistent with the relatively mild 
selective disadvantage to dogs with goniodysgenesis. Expression has also been observed in 
human tissues of mesenchymal origin such as bone and adipose. Olfactomedin like 3 is an 
extracellular matrix protein that has been implicated in the epithelial to mesenchyme transition 
in cancer (Schmitz et al. 2015), in keeping with its mesenchymal expression and suggesting 
that abnormality of this protein could be associated with the formation or retention of abnormal 
sheets of mesenchyme in the drainage angle. Olfactomedin like 3 is also proangiogenic 
(Miljkovic-Licina et al. 2012) and interacts with a member of the bone morphogenic protein 
(BMP) family, BMP4.  Since BMPs including BMP4 are involved in eye development (see 
(Pillai-Kastoori et al. 2015) for a review), this may indicate the pathway for olfactomedin like 
3 action.  
In addition, expression of OLFML3 is characteristic of microglia in humans (Butovsky et al. 
2014; Gosselin et al. 2017) and mice (Figure S3; see also (Neidert et al. 2018) and data from 
(Grabert et al. 2016)), although it is not strongly expressed by other macrophage lineages. 
Genetic manipulation resulting in absence of microglia is associated with loss of Olfml3 
expression in mice (Rojo R et al, in revision). The retina contains microglia which are important 
for retinal health (Hume et al. 1983; Karlstetter et al. 2010), and they could be one source of 
OLFML3 mRNA in the canine eye. Opening of the iridocorneal angle involves considerable 
remodelling of the mesenchymal tissue within the angle, including thinning and extending of 
the pectinate ligament and opening the trabecular meshwork (Trejo-Reveles et al. 2018). 
Microglia may contribute to this process as eye development progresses by phagocytosing 
apoptotic cells and debris from the remodelling. Abnormality of olfactomedin like 3 in the 
microglia of the eye could interfere with this function and therefore disrupt the opening of the 
iridocorneal angle and formation of the proper drainage channels.  
Olfactomedin like 3 is a member of a large family characterised by the olfactomedin (OLF) 
domain (Zeng et al. 2005; Anholt 2014), with several members expressed in eye structures. In 
particular, the glucocorticoid-inducible family member myocilin (MYOC gene) has been 
implicated in dominant open angle glaucoma in humans (Stone et al. 1997) and is strongly 
expressed in the trabecular meshwork of the drainage angle (Tamm et al. 1999; Tomarev et al. 
2003). As with Olfml3 mutants, there is no gross phenotype in Myoc knockout mice (Kim et 
al. 2001). Increased expression of Myoc mRNA resulted in a reduction in Olfml3 mRNA (Paper 
et al. 2008) in a mouse model, suggesting that there is an inverse association between these two 
OLF proteins, consistent with the expression profiles in the developing mouse eye (Figure S4) 
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where Olfml3 declined in the adult while Myoc rose. In vitro experiments indicated that 
myocilin interacts with olfactomedin 3 (also known as optimedin, encoded by the OLFM3 
gene) which was co-expressed with myocilin in the eye (Torrado et al. 2002). A variant in 
another OLF family member, OLFM2, has been associated with human open angle glaucoma 
in a small number of Japanese patients (rs779032127; p.R144Q) (Funayama et al. 2006) and 
identified as contributing to eye development (Holt et al. 2017). These other OLF family 
members may compensate for olfactomedin like 3 abnormalities, or may interact with 
olfactomedin like 3 in the development of the eye. Hence genetic variation in these family 
members may modify the impact of the OLFML3 variant in the Border Collies, explaining the 
variable phenotype of homozygotes and heterozygotes carrying the risk variant. 
A limitation to the hypothesis that the ENSCAFP00000013747.3:p.Arg197Gln variant in 
Border Collies is a risk allele for the presence of severe goniodysgenesis predisposing to 
glaucoma in homozygous animals is the observation that the variant lies outside the region of 
shared homozygosity (although within the GWAS peak) and two animals with apparently 
severe glaucoma were heterozygous. We have also seen some heterozygous animals with mild 
to moderate phenotypes (although none with glaucoma), but most heterozygotes have been 
passed as clinically unaffected at gonioscopy testing. As discussed by (Miano et al. 2000), one 
explanation would be segregation of a second allele  where compound heterozygosity also 
causes goniodysgenesis. (Wakeling et al. 2018) showed that the predictive power of 
homozygous regions is reduced where samples have greater than 8% homozygosity overall; a 
high degree of homozygosity was noted in the Border Collies in this study.  
In addition, there may be variants at modifier loci that can compensate for or exacerbate the 
effect of the OLFML3 variant. In particular, the presence of many OLF proteins in the eye and 
the mild phenotype associated with relatively broadly expressed gene family members suggests 
redundancy for at least some functions. It is also possible that inadequate compensation for the 
putative effects of the ENSCAFP00000013747.3:p.Arg197Gln variant may be responsible for 
the progression from severe goniodysgenesis to glaucoma.  
There were too few glaucoma cases in our study to allow identification of loci involved in 
progression from goniodysgenesis to glaucoma in the Border Collie and ambiguous 
phenotyping complicates the investigation of mild goniodysgenesis. The genetic relationship 
between the mild forms and the more severe forms is unknown, but the OLFML3 variant 
described here does not appear to be associated with most cases of mild goniodysgenesis 
indicating that genetic predisposition to mild goniodysgenesis may be independent of the 
findings of this study. Although testing for the OLFML3 variant (whether it is causative or in 
linkage disequilibrium with the causative DNA variant) would allow breeders to select against 
homozygotes to decrease the prevalence of the risk genotype for severe goniodysgenesis, it is 
important not to reduce the breeding pool too much because of the risk of other recessive 
conditions resulting from homozygosity for alleles that are identical by descent. Although we 
need to understand why some goniodysgenesis cases progressed to glaucoma at a young age 
and some do not, before we can make firm recommendations to the breeders of Border Collies 
worldwide, we suggest that following DNA testing dogs of all genotypes could be used 
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provided at least one partner in the mating is homozygous for the wild type allele. This would 
ensure that no homozygotes for the risk allele were produced. We would strongly advocate that 
efforts be made to maintain the breadth of the gene pool by not avoiding the use of animals that 
carry this variant. As discussed in (Farrell et al. 2015), strong selection away from variants 
serves to narrow genetic variability and can give rise to future health problems. All breeding 
decisions should be made with this, and the wider health of the breed, in mind. 
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